P
P. Andrew Futreal
Researcher at University of Texas at Austin
Publications - 32
Citations - 11582
P. Andrew Futreal is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Breast cancer & Tumor suppressor gene. The author has an hindex of 18, co-authored 32 publications receiving 10098 citations. Previous affiliations of P. Andrew Futreal include Howard Hughes Medical Institute & Wellcome Trust.
Papers
More filters
Journal ArticleDOI
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
Yoshio Miki,Jeff Swensen,Donna M Shattuck-Eidens,P. Andrew Futreal,Keith D Harshman,Sean V. Tavtigian,Qingyun Liu,Charles Cochran,L. Michelle Bennett,Wei Ding,Russell Bell,Judith Rosenthal,Charles E. Hussey,Thanh Tran,Melody McClure,Cheryl Frye,Tom Hattier,Robert Phelps,Astrid Haugen-Strano,Harold Katcher,Kazuko Yakumo,Zahra Gholami,Daniel Shaffer,Steven Stone,Steven Bayer,Christian Wray,Robert Bogden,Priya Dayananth,John R. Ward,Patricia N. Tonin,Steven A. Narod,Pam K. Bristow,Frank H. Norris,Leah M. Helvering,Paul Morrison,Paul Robert Rosteck,Mei Lai,J. Carl Barrett,Cathryn M. Lewis,Susan L. Neuhausen,Lisa A. Cannon-Albright,David E. Goldgar,Roger W. Wiseman,Alexander Kamb,Mark H. Skolnick +44 more
TL;DR: A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods.
Journal ArticleDOI
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang,Jorge Soares,Patricia Greninger,Elena J. Edelman,Howard Lightfoot,Simon A. Forbes,Nidhi Bindal,Dave Beare,James Smith,I. Richard Thompson,Sridhar Ramaswamy,P. Andrew Futreal,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Ultan McDermott,Mathew J. Garnett +16 more
TL;DR: The Genomics of Drug Sensitivity in Cancer (GDSC) provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.
Journal ArticleDOI
BRCA1 mutations in primary breast and ovarian carcinomas
P. Andrew Futreal,Qingyun Liu,Donna M Shattuck-Eidens,Charles Cochran,Keith D Harshman,Sean V. Tavtigian,L. Michelle Bennett,Astrid Haugen-Strano,Jeff Swensen,Yoshio Miki,Ken Eddington,Melody McClure,Cheryl Frye,Jane Weaver-Feldhaus,Wei Ding,Zahra Gholami,Peter Söderkvist,Lori A. Terry,Suresh C. Jhanwar,Andrew Berchuck,J. Dirk Iglehart,Jeffrey R. Marks,Dennis G. Ballinger,J. Cari Barrett,Mark H. Skolnick,Mark H. Skolnick,Alexander Kamb,Roger W. Wiseman +27 more
TL;DR: Results suggest that mutation of BRCA1 may not be critical in the development of the majority of breast and ovarian cancers that arise in the absence of a mutant germline allele.
Journal ArticleDOI
BRCA2 mutations in primary breast and ovarian cancers
Johnathan M. Lancaster,Richard Wooster,Jonathon Mangion,Catherine M. Phelan,Catherine M. Phelan,Catherine M. Phelan,Charles Cochran,Curtis Gumbs,Sheila Seal,Rita Barfoot,N. Collins,Graham R. Bignell,Sandeep Patel,Rifat Hamoudi,Catharina Larsson,Roger W. Wiseman,Andrew Berchuck,J. Dirk Iglehart,Jeffrey R. Marks,Alan Ashworth,Michael R. Stratton,P. Andrew Futreal +21 more
TL;DR: The results suggest that BRCA2 is a very infrequent target for somatic inactivation in breast and ovarian carcinomas, similar to the results obtained torBRCAL.
Journal ArticleDOI
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Thomas J. Mitchell,Samra Turajlic,Andrew Rowan,David Nicol,James H.R. Farmery,Tim O'Brien,Inigo Martincorena,Patrick S. Tarpey,Nicos Angelopoulos,Lucy R. Yates,Adam Butler,Keiran Raine,Grant D. Stewart,Ben Challacombe,Archana Fernando,José I. López,Steve Hazell,Ashish Chandra,Simon Chowdhury,Sarah Rudman,Aspasia Soultati,Gordon Stamp,Nicos Fotiadis,Lisa Pickering,Lewis Au,Lavinia Spain,Joanna Lynch,Mark Stares,Jon W. Teague,Francesco Maura,David C. Wedge,Stuart Horswell,Tim Chambers,Kevin Litchfield,Hang Xu,Aengus Stewart,Reza Elaidi,Stéphane Oudard,Nicholas McGranahan,István Csabai,Martin Gore,P. Andrew Futreal,James Larkin,Andy G. Lynch,Zoltan Szallasi,Charles Swanton,Peter J. Campbell +46 more
TL;DR: Analysis of whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma suggests that the number of cells with 3p loss capable of initiating sporadic tumors is no more than a few hundred.